TRAF4 (D1N3A) Rabbit Monoclonal Antibody #18527
- WB
Product Specifications
| REACTIVITY | H M |
| SENSITIVITY | Endogenous |
| MW (kDa) | 50 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
TRAF4, also referred to as CART1 and MLN62, is a divergent member of the TRAF family with relatively weak binding to TNFR family members (5-7). Interactions have been observed between TRAF4 and the neurotrophin receptor p75-NGFR, lymphotoxin-β receptor, and GITR (8-10). While originally identified in metastatic breast carcinoma, TRAF4 has been shown to contribute to tumor growth and invasion in various cancers including breast, lung and colon (11-13). Expression of Traf4 is induced by the tumor suppressor p53 in response to DNA damage, and can promote apoptosis (14).TRAF4 has also been shown to play a critical role in TGF-β signaling, where it has been found to antagonize the E3 ligase Smurf, resulting in enhanced receptor stabilization driving breast cancer metastasis (15).
- Arch, R.H. et al. (1998) Genes Dev 12, 2821-30.
- Chung, J.Y. et al. (2002) J Cell Sci 115, 679-88.
- Bradley, J.R. and Pober, J.S. (2001) Oncogene 20, 6482-91.
- Rothe, M. et al. (1994) Cell 78, 681-92.
- Kawamata, S. et al. (1998) J Biol Chem 273, 5808-14.
- Régnier, C.H. et al. (1995) J Biol Chem 270, 25715-21.
- Bièche, I. et al. (1996) Cancer Res 56, 3886-90.
- Yang, K. et al. (2015) Int J Clin Exp Pathol 8, 1419-26.
- Camilleri-Broët, S. et al. (2007) Oncogene 26, 142-7.
- Li, W. et al. (2013) Cancer Res 73, 6938-50.
- Ye, X. et al. (1999) J Biol Chem 274, 30202-8.
- Esparza, E.M. and Arch, R.H. (2004) Cell Mol Life Sci 61, 3087-92.
- Krajewska, M. et al. (1998) Am J Pathol 152, 1549-61.
- Sax, J.K. and El-Deiry, W.S. (2003) J Biol Chem 278, 36435-44.
- Zhang, L. et al. (2013) Mol Cell 51, 559-72.
Alternate Names
CART1; cysteine-rich domain associated with ring and TRAF domain; Cysteine-rich domain associated with RING and Traf domains protein 1; malignant 62; Metastatic lymph node gene 62 protein; MLN 62; MLN62; RING finger protein 83; RNF83; TNF receptor associated factor 4; TNF receptor-associated factor 4; TRAF4; TRAF4 variant 6; tumor necrosis receptor-associated factor 4A
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.